Sanford Consortium For Regenerative Medicine
Sanford Consortium For Regenerative Medicine maintains stable operations with declining assets and no reported officer compensation.
EIN: 208009370 · La Jolla, CA · NTEE: H05 · Updated: 2026-03-28
Is Sanford Consortium For Regenerative Medicine Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Sanford Consortium For Regenerative Medicine directs 85% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Sanford Consortium For Regenerative Medicine
Sanford Consortium For Regenerative Medicine (EIN: 208009370) is a nonprofit organization based in La Jolla, CA, classified under NTEE code H05. The organization reported total revenue of $10.0M and total assets of $83.4M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Sanford Consortium For Regenerative Medicine's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Sanford Consortium For Regenerative Medicine with a Mission Score of 80 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 10%
- programs: 85%
- fundraising: 5%
According to IRS 990 filings, Sanford Consortium For Regenerative Medicine allocates its expenses as follows: admin: 10%, programs: 85%, fundraising: 5%. With 85% directed toward programs, this reflects a strong commitment to its charitable mission.
Executive Compensation Analysis
The organization consistently reports 0% officer compensation on its IRS 990 filings, which is highly unusual for an organization of its size ($8-9 million in annual expenses) and suggests that executive compensation may be paid by a related entity or not directly reported in this section, warranting further investigation for full transparency.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Sanford Consortium For Regenerative Medicine's IRS 990 filings:
- Consistent 0% officer compensation reported on 990 Part VII, which is unusual for an organization of this scale and may obscure actual executive compensation arrangements.
- Significant expense spikes in 2016 ($19.8M) and 2015 ($12.5M) that considerably exceeded revenues, indicating potential large, unexplained expenditures or operational losses in those years.
- Steady decline in total assets from $117.2M in 2014 to $84.9M in 2023, which, while accompanied by a decrease in liabilities, warrants further investigation into asset management and long-term financial health.
Strengths
The following positive indicators were identified for Sanford Consortium For Regenerative Medicine:
- Consistent revenue generation, generally in the $8-9 million range annually, indicating stable operational funding.
- Long and consistent IRS 990 filing history (13 filings), demonstrating strong compliance and transparency in public reporting.
- Liabilities have decreased from $60.8M in 2014 to $47.9M in 2023, suggesting effective debt management and a strengthening balance sheet relative to liabilities.
Frequently Asked Questions about Sanford Consortium For Regenerative Medicine
Is Sanford Consortium For Regenerative Medicine a legitimate charity?
Based on AI analysis of IRS 990 filings, Sanford Consortium For Regenerative Medicine (EIN: 208009370) some concerns. Mission Score: 80/100. 3 red flags identified, 3 strengths noted.
How does Sanford Consortium For Regenerative Medicine spend its money?
Sanford Consortium For Regenerative Medicine directs 85% of its spending to programs and services. The remaining budget covers administration and fundraising costs.
Are donations to Sanford Consortium For Regenerative Medicine tax-deductible?
Sanford Consortium For Regenerative Medicine is registered as a tax-exempt nonprofit (EIN: 208009370). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
How is executive compensation handled if 0% is reported on the 990?
The consistent reporting of 0% officer compensation across all available filings suggests that executive compensation might be paid by a related organization, or through a different mechanism not captured in Part VII of the 990, rather than directly by the Sanford Consortium For Regenerative Medicine itself. This warrants further inquiry to understand the full compensation structure.
What caused the significant expense spikes in 2016 and 2015?
In 2016, expenses were $19,832,456 against revenues of $8,578,381, and in 2015, expenses were $12,515,545 against revenues of $8,185,564. These periods show expenses significantly exceeding revenues, which could indicate major capital expenditures, specific research project costs, or other one-time outlays. A deeper dive into the detailed financial statements for those years would be necessary to understand the nature of these expenditures.
Why have total assets been steadily declining since 2014?
Total assets have decreased from $117,252,665 in 2014 to $84,972,160 in 2023. This consistent decline, while liabilities have also decreased, could be due to depreciation of fixed assets, strategic divestments, or the utilization of endowment funds. Understanding the composition of these assets and the reasons for their reduction would provide more insight into the organization's long-term financial strategy.
Filing History
IRS 990 filing history for Sanford Consortium For Regenerative Medicine showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Sanford Consortium For Regenerative Medicine's revenue has declined by 73.1%, moving from $31.4M to $8.5M. Total assets decreased by 37.5% over the same period, from $136.0M to $85.0M. Total functional expenses rose by 457.9%, from $1.6M to $9.2M. In its most recent filing year (2023), Sanford Consortium For Regenerative Medicine reported a deficit of $735K, with expenses exceeding revenue. The organization holds $47.9M in liabilities against $85.0M in assets (debt-to-asset ratio: 56.4%), resulting in net assets of $37.0M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. | |
|---|---|---|---|---|---|---|
| 2023 | $8.5M | $9.2M | $85.0M | $47.9M | — | — |
| 2022 | $8.2M | $8.5M | $87.3M | $49.9M | — | — |
| 2021 | $8.3M | $9.2M | $91.1M | $52.9M | — | View 990 |
| 2020 | $7.9M | $8.0M | $94.5M | $55.5M | — | View 990 |
| 2019 | $8.1M | $8.4M | $96.5M | $57.4M | — | View 990 |
| 2018 | $8.2M | $8.2M | $99.1M | $59.8M | — | View 990 |
| 2017 | $8.2M | $9.7M | $101.5M | $62.3M | — | View 990 |
| 2016 | $8.6M | $19.8M | $105.5M | $64.7M | — | View 990 |
| 2015 | $8.2M | $12.5M | $110.7M | $58.6M | — | View 990 |
| 2014 | $7.8M | $12.2M | $117.3M | $60.9M | — | View 990 |
| 2013 | $7.8M | $11.5M | $123.3M | $62.5M | — | View 990 |
| 2012 | $19.6M | $10.2M | $129.8M | $65.3M | — | View 990 |
| 2011 | $31.4M | $1.6M | $136.0M | $80.9M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $8.5M, expenses of $9.2M, and assets of $85.0M (revenue +3.0% year-over-year).
- 2022: Revenue of $8.2M, expenses of $8.5M, and assets of $87.3M (revenue -0.7% year-over-year).
- 2021: Revenue of $8.3M, expenses of $9.2M, and assets of $91.1M (revenue +4.2% year-over-year).
- 2020: Revenue of $7.9M, expenses of $8.0M, and assets of $94.5M (revenue -2.5% year-over-year).
- 2019: Revenue of $8.1M, expenses of $8.4M, and assets of $96.5M (revenue -1.2% year-over-year).
- 2018: Revenue of $8.2M, expenses of $8.2M, and assets of $99.1M (revenue +0.9% year-over-year).
- 2017: Revenue of $8.2M, expenses of $9.7M, and assets of $101.5M (revenue -4.8% year-over-year).
- 2016: Revenue of $8.6M, expenses of $19.8M, and assets of $105.5M (revenue +4.8% year-over-year).
- 2015: Revenue of $8.2M, expenses of $12.5M, and assets of $110.7M (revenue +4.6% year-over-year).
- 2014: Revenue of $7.8M, expenses of $12.2M, and assets of $117.3M (revenue +0.8% year-over-year).
- 2013: Revenue of $7.8M, expenses of $11.5M, and assets of $123.3M (revenue -60.4% year-over-year).
- 2012: Revenue of $19.6M, expenses of $10.2M, and assets of $129.8M (revenue -37.6% year-over-year).
- 2011: Revenue of $31.4M, expenses of $1.6M, and assets of $136.0M.
Data Sources and Methodology
This transparency report for Sanford Consortium For Regenerative Medicine is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.